Informations générales (source: ClinicalTrials.gov)
Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients with Advanced Sarcomas Receiving Second Line Treatment.
Interventional
N/A
Centre Oscar Lambret (Voir sur ClinicalTrials)
mai 2024
mars 2028
10 septembre 2025
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised
care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas
receiving second-line treatment.
Participants will be randomised to an experimental group or a control group. Patients in
the experimental group will receive the dematerialised PCP in addition to the standard
PCP while patients in the control group will receive the standard PCP alone.
All patients will be followed until the end of second-line treatment, the start of a new
line of treatment, or until the 24-month follow-up.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Benjamin VERRET, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Eugène Marquis - 35042 - Rennes - Bretagne - France | Perrine VUAGNAT, MD | Contact (sur clinicalTrials) | |||
| Centre Léon Bérard - 69373 - Lyon - Auvergne-Rhône-Alpes - France | Armelle DUFRESNE, MD | Contact (sur clinicalTrials) | |||
| Centre Oscar Lambret - 59020 - Lille - Hauts-de-France - France | Diane PANNIER, MD | Contact (sur clinicalTrials) | |||
| CHU de Poitiers - 86021 - Poitiers - Nouvelle-Aquitaine - France | Marjorie HIRSCH, MD | Contact (sur clinicalTrials) | |||
| CHU Jean Minjoz - 25000 - Besançon - Bourgogne-Franche-Comté - France | Loic CHAIGNEAU, MD | Contact (sur clinicalTrials) | |||
| Hôpital Pitié-Salpêtrière AP-HP - 75013 - Paris - Île-de-France - France | Aurore VOZY, MD | Contact (sur clinicalTrials) | |||
| Institut Claudius Regaud - 31059 - Toulouse - Occitanie - France | Contact (sur clinicalTrials) | ||||
| Institut de Cancérologie de l'Ouest - 44805 - Saint-Herblain - Pays De La Loire - France | Emmanuelle BOMPAS, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie Strasbourg - 67033 - Strasbourg - Grand Est - France | Sophie MARTIN, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Sarcomas of soft tissues or viscera ;
- Inoperable metastatic or locally advanced disease ;
- Indication for 2nd-line treatment with pazopanib, trabectedine, eribulin, ifosfamide
or dacarbazine after failure of 1st-line anthracycline therapy ;
- Patient covered by French social security ;
- Written, signed, informed consent ;
- Sarcomas of soft tissues or viscera ;
- Inoperable metastatic or locally advanced disease ;
- Indication for 2nd-line treatment with pazopanib, trabectedine, eribulin, ifosfamide
or dacarbazine after failure of 1st-line anthracycline therapy ;
- Patient covered by French social security ;
- Written, signed, informed consent ;
- Poor understanding of French ;
- Difficulty accessing a computer ;
- Pregnant or nursing woman ;
- Person deprived of liberty or under guardianship ;
- Impossibility of undergoing medical follow-up for geographical, social or
psychological reasons.